{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T15:39:16Z","timestamp":1781710756112,"version":"3.54.5"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T00:00:00Z","timestamp":1693872000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T00:00:00Z","timestamp":1693872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>In recent years, several bispecific antibodies (BsAbs) have been introduced that revolutionized the treatment approach for patients with multiple myeloma (MM). In the present study, we sought for conducting a systematic review and meta-analysis with the aim of evaluating the safety and efficacy of BsAbs in MM patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>PubMed, Scopus, Web of Science, and Embase databases were systematically searched on June 10, 2022. Two steps of title\/abstract and full-text screening were performed for selecting the relevant articles. The primary endpoint was considered to evaluate the safety of BsAbs by examining the rate of hematologic and non-hematologic adverse effects (AEs). The secondary outcome was set at the efficacy of BsAbs through pooling objective response rate (ORR), (stringent) complete response (sCR\/CR), very good partial response (VGPR), and partial response (PR).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Eleven publications with a total of nine evaluable BsAbs were included for qualitative and quantitative data synthesis. Hematologic AEs were more common among patients than non-hematologic events, with the most frequent events being anemia (41.4%), neutropenia (36.4%), and thrombocytopenia (26.3%). The most common non-hematological AE was infection, which occurred in 39.9% of patients, followed by dysgeusia (28.3%), fatigue (26.5%), and diarrhea (25.8%). Besides, 8.1% of patients experienced immune effector cell-associated neurotoxicity syndrome and neurotoxicity occurred in 5.1% of them. Moreover, 59.8% of patients experienced cytokine release syndrome. The pooled rate of deaths attributable to BsAbs was estimated at 0.1%. In terms of efficacy measures, the ORR was achieved in 62.6% of MM patients, and the pooled rates of sCR\/CR, VGPR, and PR were 22.7%, 23.0%, and 12.1%, respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In an era with several emerging promising treatments for MM, BsAbs have achieved a high ORR and tolerable AEs in heavily pretreated patients. However, there is still room for developing BsAbs with a lower rate of AEs and capable of bypassing tumor evasion mechanisms.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12935-023-03045-y","type":"journal-article","created":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T09:02:10Z","timestamp":1693904530000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Safety and efficacy of T-cell-redirecting bispecific antibodies for patients with multiple myeloma: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"23","author":[{"given":"Maryam","family":"Noori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niloufar","family":"Yazdanpanah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nima","family":"Rezaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,5]]},"reference":[{"issue":"1","key":"3045_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. Cancer J Clin. 2019;69(1):7\u201334.","journal-title":"Cancer J Clin"},{"issue":"1","key":"3045_CR2","doi-asserted-by":"publisher","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","volume":"3","author":"SK Kumar","year":"2017","unstructured":"Kumar SK, Rajkumar V, Kyle RA, van Duin M, Sonneveld P, Mateos M-V, et al. Multiple myeloma. Nat Rev Dis Primers. 2017;3(1):17046.","journal-title":"Nat Rev Dis Primers"},{"issue":"11","key":"3045_CR3","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","volume":"364","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046\u201360.","journal-title":"N Engl J Med"},{"key":"3045_CR4","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ctrv.2018.09.001","volume":"70","author":"P Robak","year":"2018","unstructured":"Robak P, Drozdz I, Szemraj J, Robak T. Drug resistance in multiple myeloma. Cancer Treat Rev. 2018;70:199\u2013208.","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"3045_CR5","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3390\/cancers12020407","volume":"12","author":"V Pinto","year":"2020","unstructured":"Pinto V, Bergantim R, Caires HR, Seca H, Guimar\u00e3es JE, Vasconcelos MH. Multiple myeloma: available therapies and causes of drug resistance. Cancers. 2020;12(2):407.","journal-title":"Cancers"},{"issue":"1","key":"3045_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/2515135518763280","volume":"6","author":"E Dahl\u00e9n","year":"2018","unstructured":"Dahl\u00e9n E, Veitonm\u00e4ki N, Norl\u00e9n P. Bispecific antibodies in cancer immunotherapy. Ther Adv Vaccines Immunother. 2018;6(1):3\u201317.","journal-title":"Ther Adv Vaccines Immunother"},{"key":"3045_CR7","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3389\/fimmu.2020.00501","volume":"11","author":"C Caraccio","year":"2020","unstructured":"Caraccio C, Krishna S, Phillips DJ, Sch\u00fcrch CM. Bispecific antibodies for multiple myeloma: a review of targets, drugs, clinical trials, and future directions. Front Immunol. 2020;11:501.","journal-title":"Front Immunol"},{"issue":"8","key":"3045_CR8","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","volume":"18","author":"AF Labrijn","year":"2019","unstructured":"Labrijn AF, Janmaat ML, Reichert JM, Parren PW. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discovery. 2019;18(8):585\u2013608.","journal-title":"Nat Rev Drug Discovery"},{"key":"3045_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00521-4","author":"NW van de Donk","year":"2023","unstructured":"van de Donk NW, Zweegman S. T-cell-engaging bispecific antibodies in cancer. Lancet. 2023. https:\/\/doi.org\/10.1016\/S0140-6736(23)00521-4.","journal-title":"Lancet"},{"issue":"1","key":"3045_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13643-021-01626-4","volume":"10","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;10(1):1\u201311.","journal-title":"Syst Rev"},{"issue":"9","key":"3045_CR11","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","volume":"73","author":"K Slim","year":"2003","unstructured":"Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (MINORS): development and validation of a new instrument. ANZ J Surg. 2003;73(9):712\u20136.","journal-title":"ANZ J Surg"},{"issue":"Supplement1","key":"3045_CR12","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1182\/blood-2019-122895","volume":"134","author":"LJ Costa","year":"2019","unstructured":"Costa LJ, Wong SW, Berm\u00fadez A, de la Rubia J, Mateos M-V, Ocio EM, et al. First clinical study of the B-cell maturation antigen (BCMA) 2 + 1 T cell engager (TCE) CC-93269 in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): interim results of a phase 1 multicenter trial. Blood. 2019;134(Supplement1):143.","journal-title":"Blood"},{"issue":"Supplement 1","key":"3045_CR13","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1182\/blood-2020-134063","volume":"136","author":"SJ Harrison","year":"2020","unstructured":"Harrison SJ, Minnema MC, Lee HC, Spencer A, Kapoor P, Madduri D, et al. A phase 1 first in human (FIH) study of AMG 701, an anti-B-cell maturation antigen (BCMA) half-life extended (HLE) BiTE\u00ae (bispecific T-cell engager) molecule, in relapsed\/refractory (RR) multiple myeloma (MM). Blood. 2020;136(Supplement 1):28\u20139.","journal-title":"Blood"},{"issue":"Supplement 1","key":"3045_CR14","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1182\/blood-2021-150757","volume":"138","author":"S Kumar","year":"2021","unstructured":"Kumar S, D\u2019Souza A, Shah N, Rodriguez C, Voorhees PM, Bueno OF, et al. A phase 1 first-in-human study of Tnb-383B, a BCMA x CD3 bispecific T-cell redirecting antibody, in patients with relapsed\/refractory multiple myeloma. Blood. 2021;138(Supplement 1):900.","journal-title":"Blood"},{"key":"3045_CR15","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S2152-2650(21)01978-9","volume":"21","author":"M Levy","year":"2021","unstructured":"Levy M, Bahlis N, Raje N, Costello C, Dholaria B, Solh M, et al. MM-379: MagnetisMM-1: a study of elranatamab (PF-06863135), a B-Cell maturation antigen (BCMA)-targeted, CD3-engaging bispecific antibody, for patients with relapsed or refractory multiple myeloma (MM). Clin Lymphoma Myeloma Leuk. 2021;21:439.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"3045_CR16","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1200\/JCO.19.02657","volume":"38","author":"MS Topp","year":"2020","unstructured":"Topp MS, Duell J, Zugmaier G, Attal M, Moreau P, Langer C, et al. Anti-B-cell maturation antigen BiTE Molecule AMG 420 induces responses in multiple myeloma. J Clin Oncol. 2020;38(8):775\u201383.","journal-title":"J Clin Oncol"},{"key":"3045_CR17","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1182\/blood-2021-147983","volume":"138","author":"S Trudel","year":"2021","unstructured":"Trudel S, Cohen AD, Krishnan AY, Fonseca R, Spencer A, Berdeja JG, et al. Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed\/refractory multiple myeloma (RRMM): updated results from an ongoing phase I study. Blood. 2021;138:157.","journal-title":"Blood"},{"issue":"Supplement 1","key":"3045_CR18","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1182\/blood-2021-144921","volume":"138","author":"JA Zonder","year":"2021","unstructured":"Zonder JA, Richter J, Bumma N, Brayer J, Hoffman JE, Bensinger WI, et al. Early, deep, and durable responses, and low rates of cytokine release syndrome with REGN5458, a BCMAxCD3 bispecific monoclonal antibody, in a phase 1\/2 first-in-human study in patients with relapsed\/refractory multiple myeloma (RRMM). Blood. 2021;138(Supplement 1):160.","journal-title":"Blood"},{"key":"3045_CR19","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1182\/blood-2020-133873","volume":"136","author":"A Chari","year":"2020","unstructured":"Chari A, Berdeja JG, Oriol A, van de Donk NWCJ, Rodriguez P, Askari E, et al. A phase 1, first-in-human study of Talquetamab, a G protein-coupled receptor family C Group 5 Member D (GPRC5D) x CD3 bispecific antibody, in patients with relapsed and\/or refractory multiple myeloma (RRMM). Blood. 2020;136:40\u20131.","journal-title":"Blood"},{"issue":"10301","key":"3045_CR20","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","volume":"398","author":"SZ Usmani","year":"2021","unstructured":"Usmani SZ, Garfall AL, van de Donk NW, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab, a B-cell maturation antigen\u00d7 CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet. 2021;398(10301):665\u201374.","journal-title":"Lancet"},{"key":"3045_CR21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.8015","author":"MC Minnema","year":"2022","unstructured":"Minnema MC, Krishnan AY, Berdeja JG, Oriol Rocafiguera A, van de Donk NW, Rodr\u00edguez-Otero P, et al. Efficacy and safety of talquetamab, a G protein-coupled receptor family C group 5 member D x CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM): updated results from MonumenTAL-1. Am Soc Clin Oncol. 2022. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.8015.","journal-title":"Am Soc Clin Oncol"},{"key":"3045_CR22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk NW, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022. https:\/\/doi.org\/10.1056\/NEJMoa2203478.","journal-title":"N Engl J Med"},{"key":"3045_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/9781119536604","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"JP Higgins","year":"2019","unstructured":"Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane handbook for systematic reviews of interventions. Hoboken: John Wiley & Sons; 2019."},{"issue":"SUPPL 1","key":"3045_CR24","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1182\/blood-2021-148813","volume":"138","author":"A Chari","year":"2021","unstructured":"Chari A, Hari P, Bahlis NJ, Mateos MV, Van De Donk NWCJ, Dholaria B, et al. Phase 1b results for subcutaneous talquetamab plus daratumumab in patients with relapsed\/refractory multiple myeloma. Blood. 2021;138(SUPPL 1):161.","journal-title":"Blood"},{"issue":"6012","key":"3045_CR25","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/314628a0","volume":"314","author":"UD Staerz","year":"1985","unstructured":"Staerz UD, Kanagawa O, Bevan MJ. Hybrid antibodies can target sites for attack by T cells. Nature. 1985;314(6012):628\u201331.","journal-title":"Nature"},{"issue":"6026","key":"3045_CR26","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/316354a0","volume":"316","author":"P Perez","year":"1985","unstructured":"Perez P, Hoffman RW, Shaw S, Bluestone JA, Segal DM. Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody. Nature. 1985;316(6026):354\u20136.","journal-title":"Nature"},{"issue":"1","key":"3045_CR27","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1182\/blood-2017-06-741058","volume":"131","author":"MP Velasquez","year":"2018","unstructured":"Velasquez MP, Bonifant CL, Gottschalk S. Redirecting T cells to hematological malignancies with bispecific antibodies. Blood. 2018;131(1):30\u20138.","journal-title":"Blood"},{"issue":"5","key":"3045_CR28","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1158\/2643-3230.BCD-21-0028","volume":"2","author":"G Lancman","year":"2021","unstructured":"Lancman G, Sastow DL, Cho HJ, Jagannath S, Madduri D, Parekh SS, et al. Bispecific antibodies in multiple myeloma: Present and FutureBispecifics in multiple myeloma. Blood Cancer Discovery. 2021;2(5):423\u201333.","journal-title":"Blood Cancer Discovery"},{"key":"3045_CR29","unstructured":"Administration USFaD. FDA approves teclistamab-cqyv for relapsed or refractory multiple myeloma. 2022."},{"issue":"1","key":"3045_CR30","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1080\/16078454.2018.1549802","volume":"24","author":"J Yu","year":"2019","unstructured":"Yu J, Wang W, Huang H. Efficacy and safety of bispecific T-cell engager (BiTE) antibody blinatumomab for the treatment of relapsed\/refractory acute lymphoblastic leukemia and non-hodgkin\u2019s lymphoma: a systemic review and meta-analysis. Hematology. 2019;24(1):199\u2013207.","journal-title":"Hematology"},{"key":"3045_CR31","doi-asserted-by":"publisher","first-page":"544754","DOI":"10.3389\/fphar.2020.544754","volume":"11","author":"X Xiang","year":"2020","unstructured":"Xiang X, He Q, Ou Y, Wang W, Wu Y. Efficacy and safety of CAR-modified T cell therapy in patients with relapsed or refractory multiple myeloma: a meta-analysis of prospective clinical trials. Front Pharmacol. 2020;11:544754.","journal-title":"Front Pharmacol"},{"issue":"1","key":"3045_CR32","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","volume":"3","author":"NC Munshi","year":"2017","unstructured":"Munshi NC, Avet-Loiseau H, Rawstron AC, Owen RG, Child JA, Thakurta A, et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis. JAMA Oncol. 2017;3(1):28\u201335.","journal-title":"JAMA Oncol"},{"issue":"8","key":"3045_CR33","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328\u201346.","journal-title":"Lancet Oncol"},{"key":"3045_CR34","doi-asserted-by":"publisher","first-page":"100810","DOI":"10.1016\/j.blre.2021.100810","volume":"49","author":"AP Longhitano","year":"2021","unstructured":"Longhitano AP, Slavin MA, Harrison SJ, Teh BW. Bispecific antibody therapy, its use and risks for infection: bridging the knowledge gap. Blood Rev. 2021;49:100810.","journal-title":"Blood Rev"},{"key":"3045_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22147652","author":"M Cosenza","year":"2021","unstructured":"Cosenza M, Sacchi S, Pozzi S. Cytokine release syndrome associated with T-cell-based therapies for hematological malignancies: pathophysiology, clinical presentation, and treatment. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22147652.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3045_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-020-01001-1","volume":"13","author":"G Roex","year":"2020","unstructured":"Roex G, Timmers M, Wouters K, Campillo-Davo D, Flumens D, Schroyens W, et al. Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma. J Hematol Oncol. 2020;13(1):1\u201314.","journal-title":"J Hematol Oncol"},{"key":"3045_CR37","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000621","author":"J Kauer","year":"2020","unstructured":"Kauer J, H\u00f6rner S, Osburg L, M\u00fcller S, M\u00e4rklin M, Heitmann JS, et al. Tocilizumab, but not dexamethasone, prevents CRS without affecting antitumor activity of bispecific antibodies. J Immunother Cancer. 2020. https:\/\/doi.org\/10.1136\/jitc-2020-000621.","journal-title":"J Immunother Cancer"},{"issue":"4","key":"3045_CR38","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1002\/cpt.1396","volume":"106","author":"J Duell","year":"2019","unstructured":"Duell J, Lammers PE, Djuretic I, Chunyk AG, Alekar S, Jacobs I, et al. Bispecific antibodies in the treatment of hematologic malignancies. Clin Pharmacol Ther. 2019;106(4):781\u201391.","journal-title":"Clin Pharmacol Ther"},{"key":"3045_CR39","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3389\/fonc.2018.00285","volume":"8","author":"S Kobold","year":"2018","unstructured":"Kobold S, Pantelyushin S, Rataj F, Vom Berg J. Rationale for combining bispecific T cell activating antibodies with checkpoint blockade for cancer therapy. Front Oncol. 2018;8:285.","journal-title":"Front Oncol"},{"issue":"20","key":"3045_CR40","doi-asserted-by":"publisher","first-page":"4607","DOI":"10.1158\/1078-0432.CCR-15-0200","volume":"21","author":"G G\u00f6rg\u00fcn","year":"2015","unstructured":"G\u00f6rg\u00fcn G, Samur MK, Cowens KB, Paula S, Bianchi G, Anderson JE, et al. Lenalidomide enhances immune checkpoint blockade-induced immune response in multiple myeloma lenalidomide in combination with checkpoint blockade in multiple myeloma. Clin Cancer Res. 2015;21(20):4607\u201318.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"3045_CR41","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.ccell.2017.02.001","volume":"31","author":"J Li","year":"2017","unstructured":"Li J, Stagg NJ, Johnston J, Harris MJ, Menzies SA, DiCara D, et al. Membrane-proximal Epitope facilitates efficient T cell synapse formation by Anti-FcRH5\/CD3 and is a requirement for Myeloma Cell Killing. Cancer Cell. 2017;31(3):383\u201395.","journal-title":"Cancer Cell"},{"key":"3045_CR42","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13045-015-0213-6","volume":"8","author":"T K\u00f6hnke","year":"2015","unstructured":"K\u00f6hnke T, Krupka C, Tischer J, Kn\u00f6sel T, Subklewe M. Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19\/CD3-bispecific T cell engager antibody blinatumomab. J Hematol Oncol. 2015;8:111.","journal-title":"J Hematol Oncol"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-023-03045-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-023-03045-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-023-03045-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T12:03:56Z","timestamp":1700481836000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerci.biomedcentral.com\/articles\/10.1186\/s12935-023-03045-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,5]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3045"],"URL":"https:\/\/doi.org\/10.1186\/s12935-023-03045-y","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,5]]},"assertion":[{"value":"24 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"193"}}